JP2008513436A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513436A5
JP2008513436A5 JP2007531869A JP2007531869A JP2008513436A5 JP 2008513436 A5 JP2008513436 A5 JP 2008513436A5 JP 2007531869 A JP2007531869 A JP 2007531869A JP 2007531869 A JP2007531869 A JP 2007531869A JP 2008513436 A5 JP2008513436 A5 JP 2008513436A5
Authority
JP
Japan
Prior art keywords
azepino
indol
methylamino
tetrahydro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513436A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/002941 external-priority patent/WO2006033007A2/en
Publication of JP2008513436A publication Critical patent/JP2008513436A/ja
Publication of JP2008513436A5 publication Critical patent/JP2008513436A5/ja
Pending legal-status Critical Current

Links

JP2007531869A 2004-09-22 2005-09-12 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6h−アゼピノ[5,4,3−cd]インドール−6−オンのリン酸塩の多形性及び非晶質形態 Pending JP2008513436A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61245904P 2004-09-22 2004-09-22
US67929605P 2005-05-09 2005-05-09
PCT/IB2005/002941 WO2006033007A2 (en) 2004-09-22 2005-09-12 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Publications (2)

Publication Number Publication Date
JP2008513436A JP2008513436A (ja) 2008-05-01
JP2008513436A5 true JP2008513436A5 (cg-RX-API-DMAC7.html) 2008-10-23

Family

ID=35526956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531869A Pending JP2008513436A (ja) 2004-09-22 2005-09-12 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6h−アゼピノ[5,4,3−cd]インドール−6−オンのリン酸塩の多形性及び非晶質形態

Country Status (17)

Country Link
US (1) US7268126B2 (cg-RX-API-DMAC7.html)
EP (1) EP1799685B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008513436A (cg-RX-API-DMAC7.html)
KR (1) KR100853601B1 (cg-RX-API-DMAC7.html)
AR (1) AR051296A1 (cg-RX-API-DMAC7.html)
AT (1) ATE551345T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005286191B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0516766A (cg-RX-API-DMAC7.html)
CA (1) CA2581025C (cg-RX-API-DMAC7.html)
ES (1) ES2382950T3 (cg-RX-API-DMAC7.html)
IL (1) IL181463A (cg-RX-API-DMAC7.html)
MX (1) MX2007002461A (cg-RX-API-DMAC7.html)
NO (1) NO337938B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ554659A (cg-RX-API-DMAC7.html)
RU (1) RU2355691C2 (cg-RX-API-DMAC7.html)
TW (1) TWI365188B (cg-RX-API-DMAC7.html)
WO (1) WO2006033007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
ES2607806T5 (es) * 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP3573990B1 (en) * 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
JP2021501771A (ja) * 2017-11-03 2021-01-21 サンド・アクチエンゲゼルシヤフト 三環系ポリ(adp−リボース)ポリメラーゼ阻害剤の結晶性塩
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US649554A (en) * 1899-04-08 1900-05-15 Ferdinand Schwedtmann Electric switch.
GB8806449D0 (en) * 1988-03-18 1988-04-20 Janssen Pharmaceutica Nv Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
MXPA06000993A (es) * 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.

Similar Documents

Publication Publication Date Title
RU2007110026A (ru) ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
JP2008507556A5 (cg-RX-API-DMAC7.html)
JP2010528011A5 (cg-RX-API-DMAC7.html)
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
JP2008501714A5 (cg-RX-API-DMAC7.html)
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
HUS1700017I1 (hu) Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2007003521A3 (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2006062984A3 (en) Inhibitors of protein kinases
JP2010505027A5 (cg-RX-API-DMAC7.html)
WO2009024341A8 (en) Condensed anthran i lami de derivatives as insectisides
JP2009538861A5 (cg-RX-API-DMAC7.html)
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2009030467A8 (en) Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides
WO2007017145A3 (en) Gsk-3 inhibitors
JP2005515295A5 (cg-RX-API-DMAC7.html)
JP2008513472A5 (cg-RX-API-DMAC7.html)
IT1366567B (it) Granulati espandibili a basemdi polimeri vinilaromatici dotati di migliorata espansibilita'e procedimento per la loro preparazione
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2006054308A3 (en) Stable atorvastatin formulations
WO2007059307A3 (en) Crystalline and amorphous forms of telithromycin
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
JP2004315386A5 (cg-RX-API-DMAC7.html)